Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced leadership appointments to support its growth and expanding strategic and operational initiatives. Inovio promoted Dr. Keiko Simon to Vice President, Alliance and Program Management and Jeffrey C. Richardson to Vice President, Strategic Relations.
.
Inovio Announces Leadership Appointments
/PLYMOUTH MEETING, Pa., June 28, 2017 – Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced leadership appointments to support its growth and expanding strategic and operational initiatives. Inovio promoted Dr. Keiko Simon to Vice President, Alliance and Program Management and Jeffrey C. Richardson to Vice President, Strategic Relations.
.
Dr. Simon, who joined Inovio in 2013, will be responsible for managing the company’s relationships with its external partners including product development collaborations with MedImmune, Regeneron, and Genentech, and other collaborations. She also will direct internal project management of Inovio’s pipeline programs in development including its phase 3 program. She joined Inovio after a 20-year career at Merck in project and portfolio management, supporting the infectious disease and vaccine therapeutic areas and external partnerships.
.
Jeffrey C. Richardson joined Inovio in 2012 after serving Amgen and GSK in global communications positions. He will be responsible for directing Inovio’s media relations, human resources, government affairs and executive communications efforts.
.
Dr. J. Joseph Kim, Inovio’s President and CEO, said, “this is a transformative time for Inovio. We are moving forward in phase 3 with a cervical pre-cancer treatment; advancing multiple immunotherapy clinical programs; and collaborating with multiple strategic partners. These two executives strengthen our management team and bring to Inovio global pharma industry experience and a track record of helping organizations reach their goals.”
.
About Inovio Pharmaceuticals, Inc.
Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Regeneron, Genentech, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more information, visit www.inovio.com.